A board-certified neurologist and pharmacist, Friedrich is Oxular’s Chief Medical Officer and has over 20 years of experience in leading clinical and translational research in industry and academia. For more than a decade he has successfully headed clinical development programs in the US, Europe, and Asia. Friedrich was previously a key strategic contributor for retinal …
Rafiq is the CEO of Complement Therapeutics, a life sciences company aiming to develop the next generation of complement medicines. Rafiq has pursued a successful career in the pharmaceutical industry globally, including senior positions in ophthalmology with Bayer and Novartis. Most recently as Senior Vice President and Global Head of Ophthalmology at Bayer, Rafiq grew …
Jim is the Chief Business Officer for Oxular. He is an accomplished and seasoned business development and strategy executive with over 20 years of creating value for pharma/biotech companies and their stakeholders. His prior work experience includes extensive experience as CBO at Rubius Therapeutics (a Flagship company focused on red blood cell therapies for oncology and auto-immune), Janssen, Alcon/Novartis and executive leadership roles at several boutique investment banks. Jim built and led the business development and M&A teams at Alcon for approximately 10 years where he was responsible for external growth strategies for its three global franchises in surgical, pharma, and consumer.
V-Bio Ventures finds, builds, and finances innovative life sciences companies. The company invests throughout Europe in start-up and early-stage companies with high growth potential as well as in technologies that provide transformational improvements in biopharmaceutical, pharmaceutical, and diagnostics markets. V-Bio Ventures works closely with Belgium-based VIB, one of the world’s premier life science institutes, with …
NeoMed is an international venture capital firm that has been supporting entrepreneurs and businesses in healthcare since 1997. Neomed invests in companies developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device, and diagnostics industries. Since inception, NeoMed has successfully invested in more than forty companies in Europe, including …
IP Group is a leading intellectual property commercialization company. It focuses on evolving great ideas, from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas – and the resulting businesses – by providing access to business-building expertise, capital (through its 100%-owned, FCA-authorized subsidiaries: IP Capital and Parkwalk …
Forbion is a leading European venture capital firm that helps companies bridge research and development through the team’s expertize in drug development and company building. Forbion is signatory to the United Nations Principles for Responsible Investment, further demonstrating its philosophy that investments in companies should positively impact the health and wellbeing of patients. It currently …
Ronald is co-founder, Chief Scientific Officer, and a Board Observer of Oxular. With more than 30 years of medical device and drug product development experience, Ronald has led multi-disciplinary technical teams, clinical trial development, and product registration in the US, the EU, China, and Brazil. His ophthalmic experience includes the development of novel microcatheters for …
Thomas is co-founder, CEO, and a Board member of Oxular. He is an experienced and successful entrepreneur who has helped to build previous private-equity-backed ventures. He was formerly co-founder and CEO of ophthalmic pharmaceutical company Aciex Therapeutics, where he brought its lead program to NDA and led the company through a successful M&A exit. His …
David is Chair of Oxular and has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the company through a successful NASDAQ listing …
Our Site
General Contact
+44 (0)1865 636200
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Media Contact
Ben Atwell / Alex Davis
FTI Consulting
London
Limited company registered in England and Wales (Registration No. 09331313)
VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting